Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Vlad Coric received an equity award of 4,545 Class A Ordinary Shares at no cost, reported as a grant under the company’s 2020 Independent Director Equity Incentive Plan. The award consists of restricted stock units scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the plan and award terms. Following this grant, Coric directly holds 15,343 Class A Ordinary Shares.
Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Bonnie L. Bassler received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. These units were granted at no cash cost and increase her directly held position to 78,492 shares.
The award was granted under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan and is generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to plan and award terms. This is a routine, compensation-related grant rather than an open-market share purchase or sale.
Royalty Pharma plc reported the voting results from its 2026 Annual General Meeting of Shareholders. Shareholders representing 508,180,103 Class A and Class B shares, or 88.08% of eligible voting power, were present or represented, providing a strong quorum.
All nine director nominees were elected to serve until the 2027 annual meeting. Shareholders approved, on a non-binding advisory basis, compensation for named executive officers and the U.K. directors’ remuneration report. They also ratified Ernst & Young LLP as independent registered public accounting firm and re-appointed Ernst & Young as U.K. statutory auditor.
Shareholders authorized the board to determine the U.K. auditor’s remuneration, approve terms for potential repurchases of Class A ordinary shares, and grant the board authority to allot shares, including authority to allot shares without rights of pre-emption.
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through entity TPC RP EPA1 LLC, reported an open-market sale of 64,399 Class A Ordinary Shares on May 26, 2026 at a weighted average price of $53.9778 per share, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, that entity held no remaining shares, while other reported direct and indirect accounts continued to hold Class A Ordinary Shares.
Royalty Pharma plc entered into a new $1.8 billion unsecured revolving credit facility with Bank of America and a syndicate of lenders. This facility replaces the company’s prior revolving credit agreement, and all obligations and commitments under the old facility were fully repaid and terminated at effectiveness.
The new Revolving Credit Facility bears interest at either a base rate tied to prime, federal funds plus 0.5%, or Term SOFR plus 1%, or at SOFR/alternative currency rates plus an applicable margin, with a commitment fee on unused amounts. It matures on May 22, 2031 and includes financial covenants requiring a consolidated leverage ratio at or below 4.00 to 1.00, a portfolio cash flow ratio at or below 5.00 to 1.00, and a coverage ratio at or above 2.50 to 1.00, with slightly higher leverage and cash flow limits following qualifying material acquisitions.
Royalty Pharma plc (RPRX) common shares are subject to a planned sale of 64,399 shares by TPC RP EPA1 LLC for the account of Terrance Coyne, an officer. The approximate sale date is May 26, 2026, and the reported aggregate market value is $3,468,530.14. The sale is made in connection with a selling plan dated February 24, 2026, intended to comply with Rule 10b5-1(c). The shares were acquired as compensation through performance awards on May 8, 2025, February 11, 2026, and May 6, 2026.
Royalty Pharma plc EVP Marshall Urist reported an open-market sale of Class A Ordinary Shares. On May 20, 2026, he sold 13,684 shares at a weighted average price of $52.7505 per share in multiple transactions between $52.62 and $52.96.
After the sale, Urist directly owned 18,197 Class A Ordinary Shares and indirectly owned 19,020 shares through an IRA. All reported transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, indicating a scheduled disposition rather than an opportunistic trade.
Royalty Pharma plc officer Marshall Urist reported a proposed sale of 13,684 shares of common stock, with an approximate sale date of May 20, 2026, and an aggregate market value of $721,837.21. The proposed sale is tied to a Rule 10b5-1 plan with a reported adoption or instruction date of February 12, 2026.
Urist also reported selling 13,684 shares on May 14, 2026, for gross proceeds of $726,137.82 during the preceding three months.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported an open-market sale of 13,684 Class A Ordinary Shares on May 14, 2026 at a weighted average price of $53.0647 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026.
Following the sale, Urist directly holds 31,881 Class A Ordinary Shares and indirectly holds 19,020 shares through an IRA. The sale price reflected multiple transactions within a range of $52.88 to $53.25 per share.
Royalty Pharma plc director Gregory Norden reported an open-market sale of Class A Ordinary Shares. On May 14, 2026, he sold 3,045 shares at $53.00 per share. After this transaction, he directly holds 191,803 Class A Ordinary Shares.
The filing notes the trade was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, indicating the sale timing was scheduled in advance rather than decided opportunistically.